Aurinia Pharmaceuticals (AUPH) Payables (2016 - 2026)

Aurinia Pharmaceuticals' Payables history runs 11 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• Quarterly Payables fell 36.94% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (down 36.94% YoY) and the FY2025 annual result came in at $3.3 million, down 36.13% from the prior year.
• Payables was $2.7 million for Q1 2026 at Aurinia Pharmaceuticals, down from $3.3 million in the prior quarter.
• Across five years, Payables topped out at $56.8 million in Q3 2024 and bottomed at $2.2 million in Q3 2025.
• A 5-year average of $27.2 million and a median of $32.4 million in 2022 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables soared 82.7% — and 2025, when it sank 96.1%.
• Aurinia Pharmaceuticals' Payables stood at $40.0 million in 2022, then slumped by 89.18% to $4.3 million in 2023, then climbed by 19.88% to $5.2 million in 2024, then slumped by 36.13% to $3.3 million in 2025, then dropped by 19.68% to $2.7 million in 2026.
• Business Quant data shows AUPH's Payables at $2.7 million in Q1 2026, $3.3 million in Q4 2025, and $2.2 million in Q3 2025.